Allergic rhinitis
Conditions
Interventions
Control group:Specific immunotherapy was performed by subcutaneous injection of allergens, once a week for 16 consecutive weeks, and then changed to once every 4 weeks.
Experimental Group:Subcutaneous injection of Sipukibart injection. The initial dose is 600mg, and then every 2 weeks, 300mg each time.
Sponsors
Tongji Hospital of Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old, gender not limited; 2. Those who meet the standards of the "Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022)", have positive serum specific IgE or positive skin prick test, and whose condition is not well controlled by commonly used drugs at present; 3. The patient or his/her legal representative can understand and sign the informed consent form; 4. Be willing and able to cooperate in completing all the examinations and follow-ups required for the research. 5. The control group consisted of those who were positive for dust mite allergens and were willing to undergo subcutaneous desensitization treatment.
Exclusion criteria
Exclusion criteria: 1. Severe systemic diseases such as severe cardiopulmonary dysfunction, liver and kidney insufficiency, severe immune deficiency or a history of malignant tumors; 2. Those who are allergic to the research drug or its excipients; 3. Those who have participated in other clinical trials within the past three months; 4. Pregnant or lactating women; 5. Other circumstances where the researcher deems it unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score,TNSS;Total Ocular Symptom Score,TOSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Rhinoconjunctivitis Quality of Life Questionnaire Score,RQLQ;Drug score;Nasal nitric oxide test;Olfactory function score; | — |
Countries
China
Contacts
Public ContactShaoqing Yu
Tongji Hospital of Tongji University
Outcome results
None listed